ENTRY       D02800                      Drug
NAME        Alefacept (USAN/INN);
            Amevive (TN)
FORMULA     C3264H5002N840O988S20
EXACT_MASS  72414.14
MOL_WEIGHT  72458.9759
SEQUENCE    FSQQIYGVVY GNVTFHVPSN VPLKEVLWKK QKDKVAELEN SEFRAFSSFK NRVYLDTVSG
            SLTIYNLTSS DEDEYEMESP NITDTMKFFL YVDKTHTCPP CPAPELLGGP SVFLFPPKPK
            DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV
            LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL
            VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
            HEALHNHYTQ KSLSLSPGK
            (Disulfide bridge: 98-98', 101-101', 133-193, 239-297, 133'-193', 239'-297')
  TYPE      Peptide
REMARK      ATC code: L04AA15
EFFICACY    Antipsoriatic, Immunosuppressant
COMMENT     Alefacept is a fusion protein combining the first extracellular domain of LFA3 [HSA:965] [KO:K06492] with constant regions, CH2 and CH3.
            LFA-3Ig
            Treatment of plaque psoriasis
TARGET      CD58 (LFA3) [HSA:965] [KO:K06492]
  PATHWAY   hsa04514(965)  Cell adhesion molecules
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AA Selective immunosuppressants
                 L04AA15 Alefacept
                  D02800  Alefacept (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Cell adhesion molecules: Ig superfamiy
               CD2 family
                CD58 (LFA3)
                 D02800  Alefacept (USAN/INN)
DBLINKS     CAS: 222535-22-0
            PubChem: 17396958
///
